Trial Profile
Immunogenicity and Safety Study of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Subjects Seven Years and Older (209762)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 09 Jun 2022
Price :
$35
*
At a glance
- Drugs Measles mumps and rubella virus vaccine-(Priorix) (Primary) ; Measles mumps and rubella virus vaccine
- Indications Measles; Mumps; Rubella
- Focus Pharmacodynamics; Registrational
- Sponsors GlaxoSmithKline; GlaxoSmithKline Biologicals; GSK
- 06 Jun 2022 According a GlaxoSmithKline media release, company announced that the US Food and Drug Administration (FDA) has approved PRIORIX (Measles, Mumps and Rubella Vaccine, Live) for active immunization for the prevention of measles, mumps and rubella (MMR) in individuals 12 months of age and older.
- 24 Nov 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 06 Jul 2015 According to the ClinicalTrials.gov record, planned end date changed from 1 Oct 2015 to 1 Sep 2015.